San Diego—The trend of delaying allogeneic hematopoietic cell transplantation (allo-HCT) in multiple myeloma (MM) may be reducing the likelihood of extended survival in high-risk patients, according to data including long-term follow-up from a prospective trial. Although autologous-allogeneic (auto-allo) transplant has not shown a consistent overall survival (OS) advantage over tandem autologous-autologous (auto-auto) transplantation in published studies, there is a growing body of